The Target's Playbook: How a Startup Actually Gets Acquired by Big Pharma

Article 1 of 2 in The M&A Playbook: Both Sides of the Table Series

A plain-language guide to positioning your company to be bought — and on your own terms

Prepared by Richstorm.co

KEY TAKEAWAYS

• Identify buyer fit using public earnings calls, patent-expiry data, past deal patterns, and industry conferences — not guesswork.

• An incubator residency creates visibility across the whole industry, not a reserved buyer; Poseida's JLABS-to-Roche path shows the eventual acquirer is often a different company than the host.

• Approval status, patent runway, mechanism differentiation, and competitive tension are the four levers that set your price — stage alone is not the whole story.

• Walking away from a low offer only works as leverage when your alternative is real and your fundamentals are strong; Verona Pharma shows a good outcome is possible even without it.

• A dual-track process (IPO preparation plus private sale talks) preserves optionality but is resource-intensive, and only works if both paths are genuinely credible.

Acquisition isn't a plan you execute at the end — it's the outcome of decisions made years earlier. The company that gets bought well didn't scramble to find a buyer; it built something a specific acquirer eventually couldn't ignore. This guide walks through five concrete steps, using real, sourced negotiations rather than generic advice.

Step 1: Pick Your Buyer Before They Pick You

Knowing that a company like BMS faces a steep patent cliff doesn't tell you whether your specific drug is something BMS actually wants. What closes that gap is four research habits — all using free, public information:

The deal-pattern habit is worth a second look, because it runs against a common assumption: a company that just spent billions in an area is usually building it out further, not stepping back. Merck shows the same sequencing in a different area — Verona Pharma, Cidara Therapeutics, and Terns Pharmaceuticals arrived one after another, not as an isolated bet. AbbVie shows a company can run this pattern in more than one area at once: ImmunoGen (oncology), Cerevel (neuroscience), and Apogee Therapeutics (immunology) were all part of the same broader effort to replace Humira's revenue.

None of this is a one-off finding, either. A review of 2025 earnings calls and SEC filings across ten major pharma companies — AbbVie, Amgen, Bristol Myers Squibb, GSK, J&J, Lilly, Merck, Novartis, Novo Nordisk, and Pfizer — found all ten describing capital concentrated on the same three areas: oncology and immunology, rare disease, and obesity/metabolic disease. Cross-referencing a company's stated priorities, its patent-expiry timeline, and its recent deal pattern together tells you which specific companies have the most urgent, current reason to want what you have — not just which ones are large.

Match Your Modality, Not Just Your Therapeutic Area

Therapeutic area alone isn't the full picture — modality (the underlying technology, such as antibody-drug conjugates, radiopharmaceuticals, RNA-based therapies, or cell therapy) is a separate, and sometimes more specific, axis of fit. A company can be fully committed to your disease area and still have no interest in your modality. When Novartis paid over $1 billion for Myricx Bio, an ADC company, in 2026, its head of biomedical research, Fiona Marshall, said directly the deal “reflects our strategy to scale innovative platforms, as we have with radioligand therapies.” Novartis was already deep in oncology — its single largest therapeutic area — but had deliberately stayed out of the ADC modality wave that Lilly, AbbVie, and Merck were already pursuing. The acquisition wasn't about entering a new disease area; it closed a specific modality gap inside an area Novartis already dominated.

Modality-specific waves also move somewhat independently of therapeutic area, and are worth tracking the same way you'd track a company's deal pattern. Radiopharmaceuticals are the clearest recent example: more than $13 billion has been committed to radioligand deals industry-wide since 2023 — BMS/RayzeBio, AstraZeneca/Fusion, Lilly/POINT, and Novartis/Mariana among them — largely because Novartis proved the modality itself works commercially (its radioligand drug Pluvicto reached roughly $2 billion in 2025 sales, up 42% year over year). Once one company proved the modality worked, the rest of the industry moved toward the same underlying technology, regardless of which specific cancers each company was targeting. Modality can also carry its own structural constraint worth understanding — radiopharmaceuticals depend on a scarce isotope supply, and even BMS had to pause a Phase 3 trial for lack of sufficient actinium-225, a reminder that the acquirer's ability to actually scale a modality matters as much as the underlying science.

The strongest signal of fit is both dimensions at once: a company that has stated it wants to build in your disease area, and is separately and visibly entering your specific modality, is a far more targeted approach than matching therapeutic area alone.

Step 2: Understand the Incubator Path — and Its Limits

A residency at an incubator like JLABS (Johnson & Johnson) or Eli Lilly's Gateway Labs puts your team in front of real pharma scientists and business-development staff for one to two years. JLABS's own published selection criteria require: genuinely novel science or technology, a significant unmet medical need, a credible team with real financial solvency, and alignment with the host company's strategic interests. Applicants submit a description of their science, IP position, competitive landscape, team bios, an 18-month milestone plan, and funding sources — this is a real evaluation, not a formality.

What you get once accepted: physical lab space and shared equipment (avoiding a $5–10 million buildout cost), a discounted vendor network, introductions to healthcare investors, and direct mentorship from the host company's own scientists and executives — all with no equity taken and no claim on your IP.

One honest gap: neither JLABS nor Gateway Labs publishes an acceptance rate or a success-rate statistic, unlike some well-known accelerators (Y Combinator accepts roughly 3% of applicants, for comparison). Treat any specific JLABS success-rate figure you see elsewhere with skepticism — it isn't public data.

The most important thing to understand about this path: residency is a visibility strategy, not a claim by the host company. Poseida Therapeutics is a real example — it was a JLABS alumnus, but it was Roche, not J&J, that eventually acquired it, through a direct licensing partnership Roche built separately with Poseida in 2022. The lesson for a founder: an incubator gets you visibility across the whole industry, not a reserved buyer — the company that eventually acquires you may well be a different company than the one that hosted you.

Step 3: Know What Actually Moves Your Price

Four factors drive most of your eventual sale premium. In plain terms:

• Approval status — has the FDA actually said yes to selling this drug to patients, or is it still being tested in trials? An approved drug is proven, real revenue; a drug in trials might still fail entirely.

• Patent runway — how many years remain before other companies can legally sell cheap copies (generics)? More years left means more years of exclusive, high-margin sales for whoever owns it.

• Mechanism differentiation — does the drug work in a genuinely new way, or is it essentially a copy of several other drugs already approved for the same disease? A novel mechanism can help patients the old drugs don't.

• Competitive tension — is more than one large company trying to buy you, or is there only one interested party? More interested buyers pushes the price up, the same way a house with competing offers sells for more.

A concrete comparison makes this tangible:

Premiums scale accordingly: roughly 30–60% for late-stage, not-yet-approved assets; 50–100%+ for approved drugs; and 50–150%+ when more than one acquirer is actively competing for the same asset. Stage alone doesn't determine price — a well-

differ

entiated, competitively sought Phase 2 asset can outprice a later-stage drug that only one company wants.

Step 4: Create a Process Without Looking Desperate

This does not mean simply asking for a higher price — any company can try that. It means not letting the market sense you have no alternative, because buyers lower their offers the moment they believe you have no choice but to accept. In practice:

• Keep enough cash runway that saying no to a low offer is a real option, not a bluff.

• Don't be the party visibly signaling urgency — a company publicly running low on cash, or reeling from a failed trial, has already told the buyer it has no leverage.

• When you reject a low offer, it doesn't have to mean cutting off contact forever — it means demonstrating a credible alternative and letting the buyer decide whether to come back with something better.

Three real, SEC-documented negotiations show how this plays out in practice — and that the outcome isn't guaranteed to be good:

Seagen and Avidity both show that a credible alternative — continuing to operate profitably, or completing an independent capital raise — produced a meaningfully better final price. But this isn't risk-free: the suitor might simply not come back at all, and time spent operating independently instead of closing a deal carries real cost if a trial fails or market conditions worsen in the meantime. Verona Pharma is the important counterweight — it never got a competitive auction despite years of searching, yet still closed at a strong $10 billion because its underlying asset (an already-approved, selling drug) carried the deal on its own. The honest takeaway: walking away only works as a strategy if your alternative is real and your underlying fundamentals are strong — it is not a universal negotiating trick, and bluffing it without either can leave you worse off.

Step 5: Understand the Dual-Track Reality

A “dual-track” process means a company works on two exit paths at the same time, instead of committing to one: (1) actually filing paperwork to go public — hiring bankers, preparing SEC filings, the whole process — while (2) simultaneously and often quietly negotiating a private sale with potential acquirers.

The reason to do both at once rather than picking one: committing to only a sale tells the buyer you have no backup, inviting a lower offer; committing to only an IPO means no fallback if public markets have a bad week when you need to price your shares. Running both means a company can take whichever outcome turns out better, right up until close to the finish line.

Two real examples, not hypotheticals: Metsera completed its IPO on the Nasdaq, and roughly ten months later was acquired by Pfizer for $10 billion — showing the IPO and sale paths aren't mutually exclusive over time. Carmot Therapeutics was actively preparing for a possible IPO while simultaneously negotiating a sale, and ultimately sold to Roche for $2.7 billion instead of ever going public.

The catch: running both tracks genuinely is expensive and complex — it requires two full sets of lawyers, bankers, and auditors working in parallel, and real care with information, since a buyer who suspects they're being used to inflate an IPO price may walk, and public investors who sense a sale is imminent may lose confidence in the IPO story. It only makes sense for companies with the cash and staff to genuinely run both processes at once, not as a bluff.